Vertex Pharmaceuticals Incorporated
VRTX
$435.52
$1.500.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.04% | 10.16% | 8.88% | 11.66% | 10.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.33% | 10.46% | 8.98% | 11.66% | 10.06% |
| Cost of Revenue | 12.41% | 13.10% | 18.13% | 16.63% | 17.14% |
| Gross Profit | 8.53% | 8.18% | 1.60% | 7.63% | 4.60% |
| SG&A Expenses | 12.91% | 16.52% | 22.60% | 28.83% | 40.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.52% | 13.85% | 19.09% | 19.12% | 21.78% |
| Operating Income | 7.02% | 5.50% | -4.31% | 2.03% | -3.87% |
| Income Before Tax | 1,613.67% | 1,937.26% | -106.30% | -94.33% | -93.98% |
| Income Tax Expenses | 4.63% | 4.51% | -7.93% | 3.14% | -11.90% |
| Earnings from Continuing Operations | 865.96% | 842.52% | -124.60% | -114.80% | -113.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 865.96% | 842.52% | -124.60% | -114.80% | -113.83% |
| EBIT | 7.02% | 5.50% | -4.31% | 2.03% | -3.87% |
| EBITDA | 5.96% | 4.75% | -4.30% | 2.23% | -2.70% |
| EPS Basic | 872.78% | 847.05% | -124.45% | -114.72% | -113.76% |
| Normalized Basic EPS | 5.09% | 2.36% | -5.94% | 0.72% | -1.35% |
| EPS Diluted | 810.70% | 787.39% | -125.47% | -115.87% | -114.98% |
| Normalized Diluted EPS | 5.05% | 2.18% | -5.71% | 0.93% | -1.14% |
| Average Basic Shares Outstanding | -0.51% | -0.28% | -0.11% | 0.10% | 0.19% |
| Average Diluted Shares Outstanding | -0.44% | -0.08% | -0.37% | -0.14% | -0.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |